Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at exploiting weaknesses in cancers and eradicating tumor cells but with a clear focus on patient safety and reducing side effects. In this way, we can both treat the disease and improve patient quality of life and outcomes. We have used our core expertise of protein engineering to create protein molecules that target the most common pediatric cancer as well as infamously difficult to treat cancers like acute myeloid leukemia and the solid tumors pancreatic, liver, and ovarian cancers. Utilizing well-known drug mechanisms of action and patient genomic and epigenetic markers will guide our clinical strategy as we move forward to make sure that only patients likely to benefit greatly from our biologics will be receiving them. The time is now for better cancer treatment options.
Company Details
- Employees
- 3
- Address
- Chicago, Il 60612, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.enzymebydesign.com/
- Keywords
- Waltham.
- HQ
- Chicago, IL
Enzyme By Design Questions
Enzyme By Design's website is https://www.enzymebydesign.com/
Enzyme By Design's LinkedIn profile is https://www.linkedin.com/company/enzyme-by-design
Enzyme By Design has
3 employees.
View email and phone details for 3
employees at Enzyme By Design.
Enzyme By Design's industry is
Biotechnology Research
Enzyme By Design's top competitors are
Meitheal Pharmaceuticals, Inc.,
Grove Biopharma, Inc.,
Proteintech Group,
Igenbio, Inc.,
Ppd,
Emalex Biosciences,
Enzyme Innovation Inc.,
Xeris Pharmaceuticals, Inc.,
Maia Biotechnology, Inc.,
Altathera Pharmaceuticals.
Enzyme By Design's categories are Biotechnology Research
